4427-16-1

Upstream product

• 14254-57-0 4-(chlorocarbonyl)pyridine 
• 1937-19-5 1-aminoguanidine hydrochloride 
• 54-85-3 isoniazid 
• 420-04-2 CYANAMID 
• 1123-87-1 isonicotinic acid hydrazide; hydrochloride 
• 14527-26-5 2-methylisothiourea sulphate 

Downstream Products

• 3652-17-3 3-(pyridin-4-yl)-1H-1,2,4-triazol-5-amine 
• 3652-17-3 5-(pyridin-4-yl)-1H-1,2,4-triazol-3-amine 

Relevant academic research and scientific papers

Triazole derivative and pharmaceutical use thereof

An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) STR1 or the following formula (III) STR2 wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all, have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

Pseudosymmetry and Bioisosterism in Biaryl Pyridyl Competitive Histamine H2-Receptor Antagonists

A process of drug design has previously been described that led to the synthesis of 3-amino-5--1,2,4-triazole (4), a competitive histamine H2-receptor antagonist structurally unrelated to, but more potent than, cimetidine.A QSAR study on a subset of analogues closely related to 4 showed that gastric acid antisecretory activity increased with decreasing lipophilicity.An SAR study about 4 focused on (1) pyridine substitution compatible with both unidentate and bidentate hydrogen bonding, (2) exploration of the pseudosymmetry of 4, and (3) examination of triazole and imidazole bioisosterism.This SAR study led to a definition of the minimum structural features required for antagonist activity.The pyridylamino group is not essential for activity since replacement with a methyl group results in a decrease but not loss of activity.The triazole amino group is also not essential since replacement of the triazole amino group by methyl results in very similar activity.A triazole ring nitrogen N-1 can be replaced by a CH as in imidazole 20.The same methylimidazole in 20 when appended to a methyl pyridine as in 22 produces a competitive antagonist with Schild plot slope of unity.In summary compound 22 displays the minimum features required for antagonist activity, namely a 4-substituted pyridine appended to a 4(5)-substituted imidazole ring with single nitrogen to amidine nitrogen pair distances of 5.16 and 6.42 Angstroem.